Detalhe da pesquisa
1.
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.
N Engl J Med
; 388(11): 1002-1014, 2023 Mar 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-36762851
2.
Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma.
N Engl J Med
; 389(11): 1009-1022, 2023 Sep 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37646702
3.
Smoldering Multiple Myeloma : Taking the narrow over the wide path?
Blood
; 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38427775
4.
BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms.
Blood
; 143(13): 1211-1217, 2024 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38194680
5.
Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in MajesTEC-1.
Blood
; 2024 Apr 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38657201
6.
Impact of elranatamab on quality of life: Patient-reported outcomes from MagnetisMM-3.
Br J Haematol
; 204(5): 1801-1810, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38420657
7.
Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA.
Blood
; 139(6): 835-844, 2022 02 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34289038
8.
Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE.
Blood
; 139(4): 492-501, 2022 01 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-34269818
9.
Adjusting for subsequent therapies in the TOURMALINE-MM1 study shows clinically meaningful improvement in overall survival with addition of ixazomib to lenalidomide and dexamethasone.
Haematologica
; 2024 Feb 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38426294
10.
Plain Language Summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma.
Future Oncol
; 2024 Apr 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38651976
11.
Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma.
Blood
; 137(26): 3616-3628, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33763699
12.
Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients.
Br J Cancer
; 126(5): 718-725, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34802051
13.
The role of E3 ubiquitin ligase in multiple myeloma: potential for cereblon E3 ligase modulators in the treatment of relapsed/refractory disease.
Expert Rev Proteomics
; 19(4-6): 235-246, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36342226
14.
Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma.
Haematologica
; 107(10): 2408-2417, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35354247
15.
Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial.
Br J Haematol
; 194(1): 132-139, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33822368
16.
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.
Lancet
; 396(10262): 1563-1573, 2020 11 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-33189178
17.
N-Terminal pro-brain natriuretic peptide (NTproBNP) in patients with symptomatic multiple myeloma: report from a single institution.
Ann Hematol
; 100(10): 2521-2527, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34286378
18.
The impact of COVID-19 in the management of AL amyloidosis and Immunoglobulin Deposition Disease: A single-center experience.
Eur J Haematol
; 106(3): 340-345, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-33197297
19.
Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk.
Am J Hematol
; 96(9): 1120-1130, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34062004
20.
Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
Am J Hematol
; 96(6): 708-718, 2021 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33755235